

The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 39 (previously amended): A method for treating or inhibiting atherosclerosis in a mammal comprising:

providing a P-selectin antibody for inhibiting an interaction between P-selectin and a ligand of P-selectin, and between E-selectin and a ligand of E-selectin; and  
administering said antibody to a mammal in need of such treatment so as to cause such inhibition to occur.

Claim 40 (previously amended): The method of claim 39 wherein said antibody is administered to the mammal in conjunction with a vessel-corrective technique.

Claim 41 (previously added): The method of claim 40 wherein the vessel corrective technique is selected from the group consisting of angioplasty, a stenting procedure, atherectomy, and bypass surgery.

Claim 42 (previously added): The method of claim 39 wherein said P-selectin is on a cell.

Claim 43 (previously added): The method of claim 39 wherein said cell is an endothelial cell.

Claim 44 (previously added): The method of claim 42 wherein said cell is a platelet.

Claim 45 (previously added): The method of claim 39 wherein said E-selectin is on an endothelial cell.

Claim 46 (previously added): The method of claim 39 wherein said ligand of P-selectin comprises a carbohydrate.

Claim 47 (previously added): The method of claim 39 wherein said ligand of P-selectin comprises a glycoprotein.

Claim 48 (previously added): The method of claim 39 wherein said ligand of P-selectin is selected from the group consisting of sialyl-Lewis x, sialyl-Lewis a, sialyl-Lewis x-pentasaccharide, polyactosaminoglycan, carbohydrate containing 2,6 sialic acid, Lewis x 3'-O-sulfate, heparin oligosaccharides, PSGL-1, 160 kD monospecific P-selectin ligand and lysosomal membrane glycoproteins.

Claim 49 (previously added): The method of claim 39 wherein said ligand of P-selectin is on a cell selected from the group consisting of monocytes, neutrophils, eosinophils, CD4+ T cells, CD8+ T cells, and natural killer cells.

Claim 50 (previously added): The method of claim 39 wherein said ligand of P-selectin is on a leukocyte.

Claim 51 previously added): The method of claim 50 wherein said leukocyte is a neutrophil.

Claim 52 (previously added): The method of claim 50 wherein said leukocyte is a monocyte.

Claim 53 (canceled)

Claim 54 (canceled)

Claim 55 (canceled)

Claim 56 (canceled)

Claim 57 (canceled)

Claim 58 (canceled)

Claim 59 (canceled)

Claim 60 (canceled)

Claim 61 (previously amended): The method of claim 39 wherein said antibody is an inhibitor of a molecule required for the synthesis, post-translational modification or functioning of said P-selectin or said ligand of P-selectin.

Claim 62 (previously amended): The method of claim 39 wherein said antibody inhibits interaction between said P-selectin and said ligand of P-selectin or between E-selectin and said ligand of E-selectin so as to inhibit formation of an atherosclerotic streak, or reverse a formed atherosclerotic fatty streak.

Claim 63 (previously amended): The method of claim 39 wherein said antibody inhibits interaction between said P-selectin and said ligand of P-selectin or between E-selectin and said ligand of E-selectin so as to inhibit formation of an atherosclerotic intermediate lesion, or reverse a formed atherosclerotic intermediate lesion.

Claim 64 (previously amended): The method of claim 39 wherein said antibody inhibits interaction between said P-selectin and said ligand of P-selectin or between said E-selectin and said ligand of E-selectin so as to inhibit formation of an atherosclerotic fibrous plaque, or reverse a formed atherosclerotic fibrous plaque.

Claim 65 (previously amended): The method of claim 39 wherein said antibody inhibits interaction between said P-selectin and said ligand of P-selectin or between said E-selectin and said ligand of E-selectin so as to inhibit formation of an atherosclerotic lesion after a surgical procedure for inhibiting restenosis.

Claim 66 (previously added): The method of claim 39 wherein said administering occurs prior to formation of an atherosclerotic lesion.

Claim 67 (previously added): The method of claim 39 wherein said administering occurs subsequent to formation of an atherosclerotic lesion.

Claim 68 (previously added): The method of claim 39 wherein said mammal is a human.

Claim 69 (withdrawn)

Claim 70 (withdrawn)

Claim 71 (previously amended): The method of claim 39, wherein said antibody is administered at a dose of about 0.01 to about 200 mg/kg body weight.

Claim 72 (previously amended): The method of claim 39, wherein said antibody is administered at a dose of about 1 to about 100 mg/kg body weight.

Claim 73 (previously amended): The method of claim 39, wherein said antibody further inhibits interaction between L-selectin and a ligand of L-selectin.

Claim 74 (canceled)

Claim 75 (canceled)

Claim 76 (previously amended): The method of claim 39, wherein said antibody is administered in sequential exposures over a period of hours, days, weeks, months or years.

Claim 77 (previously amended): The method of claim 39, wherein said antibody is administered repeatedly, or by controlled release delivery system.

Claim 78 (previously amended): The method of claim 39, wherein the antibody is administered in combination with other therapeutic agents.

Claim 79 (previously amended): The method of claim 39, wherein the antibody is administered as a pill, as an injection or as an implant.

Claim 80 (canceled)

Claim 81 (canceled)

Claim 82 (canceled)

Claim 83 (withdrawn)

Claim 84 (canceled)

Claim 85 (canceled)

Claim 86 (canceled)

Claim 87 (withdrawn)

Claim 88 (canceled)